


Product Name : FX1
Cat. No. : PC-60927
CAS No. : 1426138-42-2
Molecular Formula : C₁₄H₉ClN₂O₄S₂
Molecular Weight : 368.806
Target : Bcl-2
Solubility : 10 mg/mL in DMSO



Biological Activity

FX1 (BCL6 inhibitor FX1) is a potent, specific **BCL6 BTB domain** inhibitor with K_d of 7 uM, binds with a greater affinity than the natural BCL6 ligand SMRT (K_d=30 uM).

FX1 exhibits 10-fold greater inhibitory activity against the BCL6 BTB domain in reporter assays with IC₅₀ of 35 uM, displays good selectivity against a panel of 50 different kinases.

FX1 disrupts formation of the BCL6 repression complex, reactivates BCL6 target genes, suppresses ABC-DLBCL cells in vitro and in vivo, as well as primary human ABC-DLBCL specimens ex vivo.

References

Cardenas MG, et al. *J Clin Invest.* 2016 Sep 1;126(9):3351-62.

Deb D, et al. *Cancer Res.* 2017 Jun 1;77(11):3070-3081.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com